Dublin, Jan. 25, 2021 (GLOBE NEWSWIRE) -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.
The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress.
COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest.
Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And let's not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.
New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?
The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in-depth report.
Key Topics Covered:
Respiratory Infections Diagnostic Market - Strategic Situation Analysis and Impact of COVID-19
- Guide for Executives, Marketing, Sales and Business Development Staff
- Guide for Management Consultants and Investment Advisors
1. Introduction and Market Definition
2. Market Overview
2.1 Players in a Dynamic Market
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Instrumentation Supplier
2.1.4 Distributor and Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Office Labs
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Respiratory Infections
2.2.1 Upper vs. Lower - Marketing Implications
2.2.2 Understanding the Role of Pneumonia
2.2.3 Bacterial Infections
2.2.4 Tuberculosis - A Special Case
2.2.5 Viral Infections
2.2.6 Fungal and Other Pathogens
2.3 Diagnostics - A Changing Role
2.3.1 Historical Practice
2.3.2 Current Diagnostics
2.3.3 The Multiplex Vector
2.3.4 Future Diagnostics - The Question of When and Where
2.3.5 Respiratory Infection Diagnostics - The Destination
2.3.6 Diagnostics as Defensive Weapons
2.4 COVID-19
2.4.1 Signs and symptoms
2.4.2 Transmission
2.4.3 Diagnosis
2.4.4 Prevention
2.4.5 Management
2.4.6 Prognosis
2.5 Pandemic Diagnostics
2.5.1 Risk Management - Spark and Spread
2.5.2 Dx Technology - Nucleic Acid Based
2.5.3 Dx Technology - Immunoassay & Serology
2.5.4 Time to Market and Preparedness Issues
2.5.5 Unrecognized Role of Multiplex in Pandemic Management
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Syndromic Multiplexing
3.1.2 T.A.T
3.1.3 Antimicrobial Resistance Movement
3.1.4 Pandemic Mitigation
3.1.5 An Aging at Risk Population
3.2 Factors Limiting Growth
3.2.1 The Cost Curve
3.2.2 Regulation and coverage
3.2.3 Laissez Faire
3.3 Instrumentation and Automation
3.3.1 The Shrinking Multiplexing Machine
3.3.2 Bioinformatics Networking and Anonymous Reporting
3.4 Diagnostic Technology Development
3.4.1 The Key Role of Time to Result
3.4.2 Single Cell Genomics Changes the Picture
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 Pathogen Identification - A Projected Timetable of the Future
4. Respiratory Infection Diagnostics Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
5. Profiles of Key Players
- Abacus Diagnostica
- Abbott Diagnostics
- Accelerate Diagnostics
- Ador Diagnostics
- Akkoni Biosystems
- Alveo Technologies
- Applied BioCode
- Atlas Genetics
- Aus Diagnostics
- BD Diagnostics
- Biocartis
- BioFire Diagnostics
- bioMerieux
- Bio-Rad Laboratories
- Bosch Healthcare Solutions GmbH
- Cepheid
- Co-Diagnostics
- Cue Health
- Curetis
- Diagenode Diagnostics
- Diascopic
- Diasorin
- Expedeon
- Fusion Genomics
- GenePOC Diagnostics
- Genetic Signatures
- GenMark Dx
- Hologic
- Immunexpress
- Inflammatix
- Invetech
- Janssen Diagnostics
- Karius
- Lexigene
- Luminex
- Lumos Diagnostics
- Mammoth Biosciences
- Mbio Diagnostics
- Meridian Bioscience
- Mesa Biotech
- Mobidiag
- Nanomix
- Oxford Nanopore
- Panagene
- Primerdesign
- Prominex
- Qiagen (Statdx)
- Quantumdx
- Quidel
- Roche Molecular Diagnostics
- Saw Diagnostics
- Seegene
- Sensovation
- Siemens Healthineers (Fast Track Diagnostics)
- SkylineDx
- Sona Nanotech
- T2 Biosystems
- Thermo Fisher
- Veradus Labs
- Veramarx
6. The Global Market for Respiratory Infection Diagnostics
6.1 Global Market Overview by Country
6.2 Global Market by Technology - Overview
6.3 Global Market by Plex - Overview
6.4 Global Market by Place - Overview
7. Global Respiratory Infection Diagnostic Markets - By Technology
7.1 Microbiology
7.2 PCR
7.3 NGS
7.4 Immunoassay/Other
7.5 C19 Singleplex
8. Global Respiratory Infection Diagnostic Markets - by Plex
8.1 C19 Single Plex
8.2 Singleplex
8.3 Duplex/Triplex
8.4 Multiplex Technology
9. Global Respiratory Infection Diagnostic Markets - by Place
9.1 Hospital Lab
9.2 Outpatient Lab
9.3 POC
For more information about this report visit https://www.researchandmarkets.com/r/2yxre
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.